Literature DB >> 8485830

Cardiac hypertrophy and failure--a disease of adaptation. Modifications in membrane proteins provide a molecular basis for arrhythmogenicity.

J M Moalic1, D Charlemagne, P Mansier, B Chevalier, B Swynghedauw.   

Abstract

Cardiac hypertrophy is the physiological adaptation of the heart to chronic mechanical overload. Cardiac failure indicates the limits of the process. Cardiac hypertrophy is only one example of biological adaptation and results from the induction of several changes in gene expression, mostly of the fetal type, including those coding for the myosin heavy chain or the alpha-subunit of the Na+,K(+)-ATPase. From a thermodynamic point of view, the decrease in Vmax allows the heart to produce a normal tension at a lower cost. This process results from changes both in the sarcomere and in the expression of certain membrane proteins. The decrease in calcium transient is determined by several changes in membrane proteins that result in a rather fragile equilibrium in terms of calcium homeostasis. Any abnormal input in calcium will have exaggerated detrimental consequences on a hypertrophied myocyte and may cause automaticity and arrhythmias or an exaggerated response to anoxia in terms of compliance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485830

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency.

Authors:  Lisa de las Fuentes; Pablo F Soto; Brian P Cupps; Michael K Pasque; Pilar Herrero; Robert J Gropler; Alan D Waggoner; Victor G Dávila-Román
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

Review 2.  Metabolic cardiomyopathies.

Authors:  B Guertl; C Noehammer; G Hoefler
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

3.  PPARalpha-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy.

Authors:  Céline Marionneau; Franck Aimond; Sylvain Brunet; Noriko Niwa; Brian Finck; Daniel P Kelly; Jeanne M Nerbonne
Journal:  J Mol Cell Cardiol       Date:  2008-04-09       Impact factor: 5.000

4.  Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.

Authors:  Xuejing Sun; Mengli Zhou; Gaiyan Wen; Yun Huang; Junru Wu; Liping Peng; Weihong Jiang; Hong Yuan; Yao Lu; Jingjing Cai
Journal:  J Am Heart Assoc       Date:  2020-12-29       Impact factor: 5.501

Review 5.  Epigenetics and Heart Failure.

Authors:  Syeda Shegufta Ameer; Mohammad Bakhtiar Hossain; Ralph Knöll
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

6.  The other side of cardiac Ca(2+) signaling: transcriptional control.

Authors:  Alejandro Domínguez-Rodríguez; Gema Ruiz-Hurtado; Jean-Pierre Benitah; Ana M Gómez
Journal:  Front Physiol       Date:  2012-11-28       Impact factor: 4.566

Review 7.  The Cardiac Mineralocorticoid Receptor (MR): A Therapeutic Target Against Ventricular Arrhythmias.

Authors:  Michel F Rossier
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-28       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.